Amylyx(US:AMLX)2026-03-03 12:10Financial Position - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $317.0 million, expected to fund operations into 2028[525]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $317.0 million, with an accumulated deficit of $751.4 million, expected to fund operations into 2028[545]. Revenue and Loss - The company reported no product revenue for the year ended December 31, 2025, a decrease of 100% compared to $87.4 million in 2024 due to the discontinuation of RELYVRIO®/ALBRIOZA™[534][536]. - The net loss for the year ended December 31, 2025, was $144.7 million, a 52% improvement from a net loss of $301.7 million in 2024[534]. Operating Expenses - Total operating expenses decreased by 62% to $153.3 million in 2025 from $402.1 million in 2024, primarily due to a significant reduction in selling, general, and administrative expenses following a restructuring plan[534][532]. - Selling, general and administrative expenses decreased to $62.9 million in 2025 from $114.3 million in 2024, reflecting a reduction in payroll and consulting costs[541]. - Research and development expenses were $90.4 million for the year ended December 31, 2025, down 13% from $104.1 million in 2024, mainly due to reduced spending on AMX0035 for ALS[540]. Financing Activities - The company raised approximately $65.5 million in January 2025 through a public offering of 19,714,285 shares at a price of $3.50 per share[543]. - The September 2025 Offering resulted in proceeds of approximately $190.7 million, net of underwriting discounts and offering expenses, from the issuance of 20,150,000 shares at a public offering price of $10.00 per share[544]. - Net cash provided by financing activities was $257.0 million in 2025, primarily from the January and September 2025 offerings[559]. Cash Flow - Operating activities used $123.3 million of cash in 2025, primarily due to a net loss of $144.7 million, offset by $27.6 million of non-cash stock-based compensation expense[552]. - The company reported a significant decrease in net cash used in operating activities from $167.6 million in 2024 to $123.3 million in 2025, a change of 26%[551]. - Net cash provided by investing activities was $14.0 million in 2025, resulting from $246.0 million of investments maturing, offset by $231.8 million in purchases of marketable securities[557]. Future Expectations - The company expects research and development expenses to increase in the near term as it advances its clinical development activities[529]. - The company anticipates that general and administrative expenses will rise in future periods as it progresses its clinical pipeline[532]. - The company expects expenses to increase as it advances preclinical activities and clinical trials for product candidates, including avexitide, AMX0035, and AMX0114[548]. - The company anticipates incurring additional costs related to operating as a public company, including legal, accounting, and investor relations expenses[548]. Risks and Uncertainties - The company may finance operations through equity offerings, debt financings, or collaborations, but faces risks if unable to raise capital when needed[547]. - The company is unable to estimate exact working capital requirements due to numerous risks and uncertainties associated with research and development activities[549].